Low CSF somatostatin associated with response to nimodipine in patents with affective illness

Mark A. Frye, Peggy J. Pazzaglia, Mark S. George, David A. Luckenbaugh, Elizabeth Vanderham, Candace L. Davis, David R. Rubinow, Robert M. Post

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.

Original languageEnglish (US)
Pages (from-to)180-183
Number of pages4
JournalBiological psychiatry
Issue number2
StatePublished - Jan 15 2003


  • Affective illness
  • Cerebrospinal fluid
  • Nimodipine
  • Somatostatin

ASJC Scopus subject areas

  • Biological Psychiatry


Dive into the research topics of 'Low CSF somatostatin associated with response to nimodipine in patents with affective illness'. Together they form a unique fingerprint.

Cite this